Melane Sampson, Author at BioTuesdays

Developments

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

111, Inc. (NASDAQ:YI), a leading tech-enabled healthcare platform in China, reported that third quarter net revenue rose 41.6% to RMB3.35 billion, or $519.3-milion (U.S.). In a statement, Junling Liu, co-founder...

November 19, 2021

Developments

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Oravax Medical, a unit of Oramed Pharmaceuticals (NASDAQ, TASE:ORMP), and Genomma Lab Internacional (BMV:LABB) formed of a 50/50 joint venture to develop and commercialize Oravax’s oral COVID-19 vaccine candidate...

November 18, 2021

Executive Moves

Talkiatry appoints Vanessa Cao as SVP of operations

In-network psychiatric care provider, Talkiatry, appointed Vanessa Cao as SVP of operations as the company prepares for a national rollout. With more than 10 years of experience in operations, Ms. Cao joins Talkiatry...

November 17, 2021

Developments

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In addition...

November 16, 2021

Developments

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for...

November 12, 2021

Developments

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate, CRV431, will be...

November 10, 2021

Developments

Cognetivity Neurosciences presents new results at AD conference

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF; FWB:1UB) presented significant new results demonstrating the capabilities of its Integrated Cognitive Assessment (ICA) platform at the Clinical Trials on Alzheimer’s...

November 9, 2021

Developments

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

Closely held Soricimed Biopharma and Dr. Vett Lloyd, a professor in the Biology Department at Mount Allison University and head of the Lloyd Tick Lab, are collaborating to design a species-specific, microbial...

November 9, 2021

Developments

POINT Biopharma, IONETIX in Ac-225 supply agreement

POINT Biopharma Global (NASDAQ:PNT) and IONETIX, a leading cyclotron technology and isotope manufacturing company, entered into a long-term supply agreement for actinium-225 (Ac-225) to support POINT’s validation, drug...

November 9, 2021

Developments

UNITY posts positive Phase 1 data in advanced vascular eye disease

UNITY Biotechnology (NASDAQ:UBX) announced positive 24-week data from its Phase 1 single ascending dose safety study of UBX1325 in patients with advanced disease from diabetic macular edema (DME) or wet age-related...

November 9, 2021

Author - Melane Sampson

111, Inc. Q3 net revenue climbs 41.6% to RMB 3.35 billion

Oramed, Genomma Lab in JV for oral COVID-19 vaccine in Mexico; BD in Latin America

Talkiatry appoints Vanessa Cao as SVP of operations

Hepion, FibroFind report positive anti-cancer activity of CRV431 in liver cancer study

Altamira posts positive Bentrio nasal spray data in Sars-CoV-2 Delta variant

Anti-cancer mechanism of Hepion’s CRV431 to be featured at liver meeting

Cognetivity Neurosciences presents new results at AD conference

Soricimed, Mount Allison University to collaborate on novel biopesticide solution

POINT Biopharma, IONETIX in Ac-225 supply agreement

UNITY posts positive Phase 1 data in advanced vascular eye disease

Subscribe